AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 1912887 — intervention group
Group type: EXPERIMENTAL
Intervention: Amoxycillin 125 mg three times a day for seven days
Number of subjects: 232
Study 1912887 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 232
Study 6348658 — intervention group
Group type: EXPERIMENTAL
Intervention: Tinidazole IV (1.60 g in 24 h)
Number of subjects: 40
Study 6348658 — intervention group
Group type: EXPERIMENTAL
Intervention: Ornidazole IV (4 g in 4 days)
Number of subjects: 40
Study 6348658 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 31504952 — intervention group
Group type: EXPERIMENTAL
Intervention: Constraint-Induced Movement Therapy (CI therapy)
Number of subjects: 47
Study 31504952 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced probabilistic neural network model
Number of subjects: 47
Study 31504952 — intervention group
Group type: EXPERIMENTAL
Intervention: Neural dynamic classification algorithm
Number of subjects: 47
Study 28708126 — intervention group
Group type: EXPERIMENTAL
Intervention: HMB supplementation
Number of subjects: 42
Study 28708126 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 42
Study 26068295 — intervention group
Group type: EXPERIMENTAL
Intervention: Denosumab treatment for 4 years
Number of subjects: 4074
Study 26068295 — intervention group
Group type: EXPERIMENTAL
Intervention: Denosumab treatment for 7 years
Number of subjects: 4074
Study 24727329 — intervention group
Group type: EXPERIMENTAL
Intervention: erlotinib
Number of subjects: 47
Study 24727329 — intervention group
Group type: EXPERIMENTAL
Intervention: erlotinib-sulindac
Number of subjects: 47
Study 24727329 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 47
Study 22841653 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrauterine instillation of 95% tricholoroacetic acid
Number of subjects: 70
Study 22841653 — intervention group
Group type: COMPARATOR
Intervention: Topical application of 95% tricholoroacetic acid after dilatation and curettage
Number of subjects: 70
Study 20671333 — intervention group
Group type: EXPERIMENTAL
Intervention: Creative musical expression protocol
Number of subjects: 52
Study 20671333 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 52
Study 17709061 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified yoga-based exercise program (n=19)
Number of subjects: 37
Study 17709061 — intervention group
Group type: COMPARATOR
Intervention: Control group (n=18)
Number of subjects: 37
Study 15378664 — intervention group
Group type: EXPERIMENTAL
Intervention: Ginkgo biloba 240 mg daily
Number of subjects: 24
Study 15378664 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 11548847 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-APBSCT rhG-CSF administration (Group B and C)
Number of subjects: 38
Study 11548847 — intervention group
Group type: COMPARATOR
Intervention: No rhG-CSF administration (Group A)
Number of subjects: 38
Study 9740345 — intervention group
Group type: EXPERIMENTAL
Intervention: Reviparin
Number of subjects: 612
Study 9740345 — intervention group
Group type: COMPARATOR
Intervention: Unfractionated heparin/placebo
Number of subjects: 612
Study 7799246 — intervention group
Group type: EXPERIMENTAL
Intervention: Cholinergic stimulation
Number of subjects: 0
Study 7799246 — intervention group
Group type: COMPARATOR
Intervention: Healthy control subjects
Number of subjects: 0
Study 3053750 — intervention group
Group type: EXPERIMENTAL
Intervention: Ad libitum home dietary conditions (E vs Y)
Number of subjects: 18
Study 3053750 — intervention group
Group type: EXPERIMENTAL
Intervention: Very high (85%) carbohydrate diet (E)
Number of subjects: 18
Study 3053750 — intervention group
Group type: EXPERIMENTAL
Intervention: Low (30%) carbohydrate diet (Y)
Number of subjects: 18
Study 28898922 — intervention group
Group type: EXPERIMENTAL
Intervention: Cold snare endoscopic mucosal resection (CS-EMR)
Number of subjects: 155
Study 28898922 — intervention group
Group type: COMPARATOR
Intervention: Hot snare endoscopic mucosal resection (HS-EMR)
Number of subjects: 155
Study 30208765 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher-income caregivers (88% aware of nutrition labels)
Number of subjects: 100
Study 30208765 — intervention group
Group type: COMPARATOR
Intervention: Low-income caregivers (51% aware of nutrition labels)
Number of subjects: 100
Study 26678636 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher dose edoxaban (60mg/30mg dose reduced)
Number of subjects: 21105
Study 26678636 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower dose edoxaban (30mg/15mg dose reduced)
Number of subjects: 21105
Study 26678636 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher dose edoxaban
Number of subjects: 21105
Study 26678636 — intervention group
Group type: EXPERIMENTAL
Intervention: Edoxaban
Number of subjects: 21105
Study 26678636 — intervention group
Group type: COMPARATOR
Intervention: Warfarin
Number of subjects: 21105
Study 24248104 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorhexidine gluconate mouthwash 0.2%
Number of subjects: 80
Study 24248104 — intervention group
Group type: EXPERIMENTAL
Intervention: Persica™ 10%
Number of subjects: 80
Study 24248104 — intervention group
Group type: EXPERIMENTAL
Intervention: Matrica® (chamomile extracts) 10%
Number of subjects: 80
Study 24248104 — intervention group
Group type: COMPARATOR
Intervention: Normal saline
Number of subjects: 80
Study 21917021 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 mg naftopidil daily
Number of subjects: 74
Study 21917021 — intervention group
Group type: COMPARATOR
Intervention: 8 mg silodosin daily
Number of subjects: 74
Study 18709689 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral dehydroepiandrosterone (DHEA) treatment (50 mg/day)
Number of subjects: 37
Study 18709689 — intervention group
Group type: EXPERIMENTAL
Intervention: DHEA treatment in vitro
Number of subjects: 37
Study 18709689 — intervention group
Group type: COMPARATOR
Intervention: Saliva levels of resistin in pSS patients
Number of subjects: 37
Study 18709689 — intervention group
Group type: COMPARATOR
Intervention: Circulating levels of resistin
Number of subjects: 37
Study 16818971 — intervention group
Group type: EXPERIMENTAL
Intervention: Apprehension test
Number of subjects: 46
Study 16818971 — intervention group
Group type: EXPERIMENTAL
Intervention: Relocation test
Number of subjects: 46
Study 16818971 — intervention group
Group type: EXPERIMENTAL
Intervention: Anterior drawer test
Number of subjects: 46
Study 12875613 — intervention group
Group type: EXPERIMENTAL
Intervention: galantamine 24 mg/day
Number of subjects: 182
Study 12875613 — intervention group
Group type: COMPARATOR
Intervention: donepezil 10 mg/day
Number of subjects: 182
Study 10575405 — intervention group
Group type: EXPERIMENTAL
Intervention: Mycobacterium w vaccine
Number of subjects: 157
Study 10575405 — intervention group
Group type: COMPARATOR
Intervention: Placebo injection
Number of subjects: 157
Study 8724619 — intervention group
Group type: EXPERIMENTAL
Intervention: TCu 380A IUD
Number of subjects: 0
Study 1653139 — intervention group
Group type: EXPERIMENTAL
Intervention: Sumatriptan (100 mg dispersible tablet)
Number of subjects: 580
Study 1653139 — intervention group
Group type: COMPARATOR
Intervention: Cafergot (2 mg ergotamine tartrate, 200 mg caffeine)
Number of subjects: 580
Study 1653139 — intervention group
Group type: EXPERIMENTAL
Intervention: Sumatriptan
Number of subjects: 580
Study 1653139 — intervention group
Group type: COMPARATOR
Intervention: Cafergot
Number of subjects: 580
Study 6214337 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium Cromoglycate (SCG)
Number of subjects: 7
Study 6214337 — intervention group
Group type: EXPERIMENTAL
Intervention: Ipratropium Bromide
Number of subjects: 7
Study 6214337 — intervention group
Group type: EXPERIMENTAL
Intervention: Clemastine
Number of subjects: 7
Study 6214337 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketotifen
Number of subjects: 7
Study 6214337 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7
Study 30291797 — intervention group
Group type: EXPERIMENTAL
Intervention: Multimedia psychoeducation (MP) intervention
Number of subjects: 418
Study 30291797 — intervention group
Group type: COMPARATOR
Intervention: Print education (PE) intervention
Number of subjects: 418
Study 28438412 — intervention group
Group type: EXPERIMENTAL
Intervention: High-fat, low-carbohydrate (HF) meal
Number of subjects: 9
Study 28438412 — intervention group
Group type: COMPARATOR
Intervention: Low-fat, high-carbohydrate (LF) meal
Number of subjects: 9
Study 28438412 — intervention group
Group type: EXPERIMENTAL
Intervention: Theobromine added to LF meal
Number of subjects: 9
Study 26232345 — intervention group
Group type: EXPERIMENTAL
Intervention: Short phone calls
Number of subjects: 1380
Study 26232345 — intervention group
Group type: EXPERIMENTAL
Intervention: Short text messaging system (sms-text)
Number of subjects: 1380
Study 26232345 — intervention group
Group type: EXPERIMENTAL
Intervention: E-mails
Number of subjects: 1380
Study 26232345 — intervention group
Group type: COMPARATOR
Intervention: Control group (no reminders)
Number of subjects: 1380
Study 24014554 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive chelation therapy
Number of subjects: 72
Study 24014554 — intervention group
Group type: EXPERIMENTAL
Intervention: Ferritin levels above 1800 G/L
Number of subjects: 72
Study 24014554 — intervention group
Group type: COMPARATOR
Intervention: High ferritin levels
Number of subjects: 72
Study 24014554 — intervention group
Group type: EXPERIMENTAL
Intervention: Ferritin as a prognostic marker
Number of subjects: 72
Study 21383657 — intervention group
Group type: EXPERIMENTAL
Intervention: mycophenolate mofetil with microemulsified cyclosporine
Number of subjects: 830
Study 21383657 — intervention group
Group type: EXPERIMENTAL
Intervention: mycophenolate mofetil with tacrolimus
Number of subjects: 830
Study 21383657 — intervention group
Group type: COMPARATOR
Intervention: mycophenolate mofetil
Number of subjects: 830
Study 18378748 — intervention group
Group type: EXPERIMENTAL
Intervention: Polypropylene mesh repair
Number of subjects: 76
Study 18378748 — intervention group
Group type: COMPARATOR
Intervention: Anterior colporrhaphy
Number of subjects: 76
Study 17020163 — intervention group
Group type: EXPERIMENTAL
Intervention: Divator Drogsan Pharmaceuticals (test formulation)
Number of subjects: 52
Study 17020163 — intervention group
Group type: COMPARATOR
Intervention: Lipitor (reference formulation)
Number of subjects: 52
Study 15022654 — intervention group
Group type: EXPERIMENTAL
Intervention: Traditional Ayurvedic supplement
Number of subjects: 25
Study 10859081 — intervention group
Group type: EXPERIMENTAL
Intervention: 60 mg of intravenous ketorolac at the onset of the procedure (Group B)
Number of subjects: 123
Study 10859081 — intervention group
Group type: EXPERIMENTAL
Intervention: 60 mg of ketorolac mixed with local anesthetic (Group C)
Number of subjects: 123
Study 10859081 — intervention group
Group type: COMPARATOR
Intervention: Placebo (saline) injections (Group A)
Number of subjects: 123
Study 9198713 — intervention group
Group type: EXPERIMENTAL
Intervention: Middlewave broadcast stations (exposed to EMF at 1 MHz)
Number of subjects: 153
Study 9198713 — intervention group
Group type: EXPERIMENTAL
Intervention: Radioservice stations (exposed to EMF at about 150 MHz)
Number of subjects: 153
Study 9198713 — intervention group
Group type: EXPERIMENTAL
Intervention: Radio line stations (exposed to EMF)
Number of subjects: 153
Study 9198713 — intervention group
Group type: COMPARATOR
Intervention: Control group (not exposed to EMF)
Number of subjects: 153
Study 8459068 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous Solu‐Medrol (1,000 mg for 3 days)
Number of subjects: 41
Study 8459068 — intervention group
Group type: COMPARATOR
Intervention: Oral prednisone (100 mg bolus for 3 days, tapering over 14 days)
Number of subjects: 41
Study 8459068 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous Solu‐Medrol
Number of subjects: 41
Study 8459068 — intervention group
Group type: COMPARATOR
Intervention: Oral prednisone
Number of subjects: 41
Study 3541604 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral influenza vaccine (killed vaccine, 98 ug hemagglutinin of A/Bangkok)
Number of subjects: 0
Study 3541604 — intervention group
Group type: COMPARATOR
Intervention: Intramuscular influenza vaccine
Number of subjects: 0
Study 3541604 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 31523905 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive rehearsal intervention using a smartphone application
Number of subjects: 72
Study 29583015 — intervention group
Group type: EXPERIMENTAL
Intervention: 1000 mg/day resveratrol
Number of subjects: 32
Study 29583015 — intervention group
Group type: COMPARATOR
Intervention: 300 mg/day resveratrol
Number of subjects: 32
Study 29583015 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study 26537439 — intervention group
Group type: EXPERIMENTAL
Intervention: Dapagliflozin 10mg + MET + SU
Number of subjects: 216
Study 26537439 — intervention group
Group type: COMPARATOR
Intervention: Placebo + MET + SU
Number of subjects: 216
Study 25179996 — intervention group
Group type: EXPERIMENTAL
Intervention: Active tDCS over the right DLPFC (n=5)
Number of subjects: 18
Study 25179996 — intervention group
Group type: EXPERIMENTAL
Intervention: Active tDCS over the left DLPFC (n=6)
Number of subjects: 18
Study 25179996 — intervention group
Group type: COMPARATOR
Intervention: Sham tDCS (n=7)
Number of subjects: 18
Study 23663561 — intervention group
Group type: EXPERIMENTAL
Intervention: 20-meter walk test (self-selected pace)
Number of subjects: 15
Study 20199482 — intervention group
Group type: EXPERIMENTAL
Intervention: Paliperidone extended-release (ER)
Number of subjects: 1193
Study 20199482 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1193
Study 19064562 — intervention group
Group type: EXPERIMENTAL
Intervention: CYP19A1 polymorphisms (rs1004982, rs28566535, rs936306, rs4775936)
Number of subjects: 614
Study 19064562 — intervention group
Group type: EXPERIMENTAL
Intervention: Haplotypes inferred using all polymorphisms
Number of subjects: 614
Study 15898124 — intervention group
Group type: EXPERIMENTAL
Intervention: Severe preeclampsia
Number of subjects: 90
Study 15898124 — intervention group
Group type: EXPERIMENTAL
Intervention: Mild preeclampsia
Number of subjects: 90
Study 15898124 — intervention group
Group type: COMPARATOR
Intervention: Healthy pregnancy
Number of subjects: 90
Study 12788893 — intervention group
Group type: EXPERIMENTAL
Intervention: Growth Hormone (GH) infusion at a rate to raise local GH to approximately 40 ng/ml for 4 hours
Number of subjects: 8
Study 12788893 — intervention group
Group type: EXPERIMENTAL
Intervention: Growth Hormone (GH) infusion
Number of subjects: 8
Study 12788893 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 10657837 — intervention group
Group type: EXPERIMENTAL
Intervention: Defective inactivation of leukotriene B4 (LTB(4))
Number of subjects: 6
Study 10657837 — intervention group
Group type: EXPERIMENTAL
Intervention: Abnormal pattern of urinary excretion of LTB(4) and its metabolites
Number of subjects: 6
Study 10657837 — intervention group
Group type: EXPERIMENTAL
Intervention: Defective inactivation of LTB(4)
Number of subjects: 6
Study 8634616 — intervention group
Group type: EXPERIMENTAL
Intervention: Health check conducted by nurse, with health education and follow up according to degree of risk
Number of subjects: 2205
Study 8634616 — intervention group
Group type: COMPARATOR
Intervention: Control group (1916 patients who attended their initial health check in 1992‐3)
Number of subjects: 2205
Study 1486816 — intervention group
Group type: EXPERIMENTAL
Intervention: Rooming-in hospital with breastfeeding guidance (RIBFG)
Number of subjects: 165
Study 1486816 — intervention group
Group type: COMPARATOR
Intervention: Rooming-in hospital without breastfeeding guidance (RI)
Number of subjects: 165
Study 1486816 — intervention group
Group type: COMPARATOR
Intervention: Nursery (NUR)
Number of subjects: 165
Study 3899818 — intervention group
Group type: EXPERIMENTAL
Intervention: Neutral human insulin (0.3 U/kg)
Number of subjects: 12
Study 3899818 — intervention group
Group type: EXPERIMENTAL
Intervention: Acid bovine soluble insulin (0.3 U/kg)
Number of subjects: 12
Study 3899818 — intervention group
Group type: COMPARATOR
Intervention: Moderate antibody levels
Number of subjects: 12
Study 3899818 — intervention group
Group type: EXPERIMENTAL
Intervention: Acid bovine soluble insulin
Number of subjects: 12
Study 3899818 — intervention group
Group type: EXPERIMENTAL
Intervention: Neutral human insulin
Number of subjects: 12
Study 30084103 — intervention group
Group type: EXPERIMENTAL
Intervention: Rolapitant (180 mg)
Number of subjects: 20
Study 28182466 — intervention group
Group type: EXPERIMENTAL
Intervention: Spiritual Strategies for Psychosocial Recovery (SSPR)
Number of subjects: 37
Study 26650429 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylnaltrexone 12 mg
Number of subjects: 134
Study 26650429 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 134
Study 25438529 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose milk powder (55g daily)
Number of subjects: 32
Study 25438529 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose milk powder (33g daily)
Number of subjects: 32
Study 25438529 — intervention group
Group type: COMPARATOR
Intervention: Control cycle (first and third menstrual cycles)
Number of subjects: 32
Study 21711525 — intervention group
Group type: EXPERIMENTAL
Intervention: Action‐Observation Therapy (UP‐CAT)
Number of subjects: 24
Study 21711525 — intervention group
Group type: COMPARATOR
Intervention: Control group (computer games)
Number of subjects: 24
Study 16107949 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant glycoprotein 120 vaccine
Number of subjects: 368
Study 16107949 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 368
Study 12195271 — intervention group
Group type: EXPERIMENTAL
Intervention: Age-specific asthma program including assessment, education, and management by a team of asthma educators, respiratory therapists, and respiratory physicians.
Number of subjects: 93
Study 12195271 — intervention group
Group type: COMPARATOR
Intervention: Usual care from regular physicians with spirometry performed.
Number of subjects: 93
Study 9746935 — intervention group
Group type: EXPERIMENTAL
Intervention: Competence belief and resources (vitality, social contact, affection)
Number of subjects: 4792
Study 9746935 — intervention group
Group type: COMPARATOR
Intervention: Age
Number of subjects: 4792
Study 9746935 — intervention group
Group type: EXPERIMENTAL
Intervention: Competence belief
Number of subjects: 4792
Study 9746935 — intervention group
Group type: EXPERIMENTAL
Intervention: Resources (vitality, social contact, affection)
Number of subjects: 4792
Study 10150186 — intervention group
Group type: EXPERIMENTAL
Intervention: Nimodipine in subarachnoid hemorrhage
Number of subjects: 3728
Study 10150186 — intervention group
Group type: EXPERIMENTAL
Intervention: Nimodipine in ischemic stroke
Number of subjects: 3728
Study 10150186 — intervention group
Group type: COMPARATOR
Intervention: Control in subarachnoid hemorrhage
Number of subjects: 3728
Study 10150186 — intervention group
Group type: COMPARATOR
Intervention: Control in ischemic stroke
Number of subjects: 3728
Study 3179151 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.75% 10 ml (75 mg)
Number of subjects: 50
Study 3179151 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5% 15 ml (75 mg)
Number of subjects: 50
Study 3179151 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.75% 15 ml (112.5 mg)
Number of subjects: 50
Study 3179151 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.75% 10 ml (75 mg) in patients older than 50 years
Number of subjects: 50
Study 3179151 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.75% 15 ml (75 mg) in patients older than 50 years
Number of subjects: 50
Study 4412442 — intervention group
Group type: EXPERIMENTAL
Intervention: Lillehei Kaster pivoting disc valve
Number of subjects: 64
Study 4412442 — intervention group
Group type: COMPARATOR
Intervention: Bjork Shiley (Delrin) tilting disc valve
Number of subjects: 64
Study 11827248 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise
Number of subjects: 300
Study 11827248 — intervention group
Group type: COMPARATOR
Intervention: No exercise (Control)
Number of subjects: 300
Study 30883861 — intervention group
Group type: EXPERIMENTAL
Intervention: Angiotensin converting enzyme inhibitor
Number of subjects: 0
Study 30101667 — intervention group
Group type: EXPERIMENTAL
Intervention: Mini-plate (MP) fixation via sinus tarsi approach
Number of subjects: 60
Study 30101667 — intervention group
Group type: COMPARATOR
Intervention: Cannulated screw (CS) fixation
Number of subjects: 60
Study 27402210 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound therapy (10 treatments)
Number of subjects: 47
Study 27402210 — intervention group
Group type: EXPERIMENTAL
Intervention: Shock wave therapy (4 treatments)
Number of subjects: 47
Study 24762779 — intervention group
Group type: EXPERIMENTAL
Intervention: Narrative Exposure Therapy (NET)
Number of subjects: 0
Study 24762779 — intervention group
Group type: COMPARATOR
Intervention: Treatment as Usual (TaU)
Number of subjects: 0
Study 23469593 — intervention group
Group type: EXPERIMENTAL
Intervention: Chinese herbs (CMST)
Number of subjects: 170
Study 23469593 — intervention group
Group type: COMPARATOR
Intervention: Western medicine (Domperidone or Esomeprazole)
Number of subjects: 170
Study 20795924 — intervention group
Group type: EXPERIMENTAL
Intervention: Unloaded breathing
Number of subjects: 30
Study 20795924 — intervention group
Group type: EXPERIMENTAL
Intervention: Loaded breathing (20 cmH(2)O)
Number of subjects: 30
Study 20795924 — intervention group
Group type: COMPARATOR
Intervention: Comparison of loaded vs unloaded breathing
Number of subjects: 30
Study 17618958 — intervention group
Group type: EXPERIMENTAL
Intervention: 1500 mg Rhodiola rosea per day for 4 days
Number of subjects: 12
Study 17618958 — intervention group
Group type: COMPARATOR
Intervention: Placebo (equivalent dose)
Number of subjects: 12
Study 17618958 — intervention group
Group type: EXPERIMENTAL
Intervention: Rhodiola rosea
Number of subjects: 12
Study 17618958 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 17618958 — intervention group
Group type: COMPARATOR
Intervention: Rhodiola rosea and Placebo
Number of subjects: 12
Study 16356089 — intervention group
Group type: EXPERIMENTAL
Intervention: TPOAb positive (TPOAb(+) > 100 U/ml)
Number of subjects: 2775
Study 16356089 — intervention group
Group type: EXPERIMENTAL
Intervention: Earlier diagnosis of hypothyroidism
Number of subjects: 2775
Study 16356089 — intervention group
Group type: EXPERIMENTAL
Intervention: Use of thyroid medication
Number of subjects: 2775
Study 16356089 — intervention group
Group type: EXPERIMENTAL
Intervention: Low FT4 (lowest tenth percentile)
Number of subjects: 2775